National Medical Insurance Administration: For the 11th batch of centralized procurement, for companies with prices lower than the "anchor price", the leading companies are required to respond to the concerns of society about selecting lower-priced options.

On September 20th, the National Drug Centralized Purchasing Office announced the 11th batch of national organized drug centralized procurement documents. Regarding the "anti-insulation" principle of the 11th batch of centralized procurement, relevant officials from the National Medical Insurance Administration emphasized that companies are required to bid no lower than the cost price. Each bidding company is required to make a commitment not to bid lower than the cost price. For companies bidding below the "anchor price", they are required to declare the rationality of their bid, explain the specific cost composition, including manufacturing costs, period expenses, sales profits, etc., in order to respond to society's concerns about selecting low-priced options.